Northeast Pharmaceutical Group 과거 수익 실적
과거 기준 확인 1/6
Northeast Pharmaceutical Group has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 1.5% per year. Northeast Pharmaceutical Group's return on equity is 6.8%, and it has net margins of 4.3%.
주요 정보
35.5%
수익 성장률
33.8%
EPS 성장률
Pharmaceuticals 산업 성장 | 10.9% |
매출 성장률 | 1.5% |
자기자본 수익률 | 6.8% |
순이익 | 4.3% |
최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 30It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)
Aug 07These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely
May 25Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Apr 05수익 및 비용 분석
Northeast Pharmaceutical Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 7,973 | 347 | 2,056 | 108 |
30 Jun 24 | 7,905 | 380 | 2,066 | 108 |
31 Mar 24 | 7,829 | 346 | 2,270 | 101 |
31 Dec 23 | 8,243 | 358 | 2,573 | 97 |
30 Sep 23 | 8,643 | 442 | 2,839 | 146 |
30 Jun 23 | 8,895 | 373 | 3,031 | 146 |
31 Mar 23 | 8,810 | 352 | 2,913 | 152 |
01 Jan 23 | 8,809 | 350 | 2,789 | 160 |
30 Sep 22 | 8,609 | 202 | 2,727 | 106 |
30 Jun 22 | 8,555 | 151 | 2,752 | 102 |
31 Mar 22 | 8,478 | 129 | 2,776 | 93 |
31 Dec 21 | 8,145 | 99 | 2,711 | 83 |
30 Sep 21 | 8,003 | 37 | 2,613 | 62 |
30 Jun 21 | 7,671 | 14 | 2,530 | 61 |
31 Mar 21 | 7,465 | 71 | 2,458 | 69 |
31 Dec 20 | 7,384 | 12 | 2,453 | 74 |
30 Sep 20 | 7,659 | -1 | 2,751 | 76 |
30 Jun 20 | 7,833 | 113 | 2,784 | 74 |
31 Mar 20 | 8,026 | 97 | 2,901 | 73 |
31 Dec 19 | 8,220 | 174 | 3,014 | 64 |
30 Sep 19 | 7,898 | 214 | 2,880 | 137 |
30 Jun 19 | 7,828 | 198 | 2,823 | 154 |
31 Mar 19 | 7,622 | 200 | 2,724 | 148 |
31 Dec 18 | 7,467 | 195 | 2,581 | 145 |
30 Sep 18 | 7,102 | 196 | 2,443 | 73 |
30 Jun 18 | 6,659 | 196 | 2,214 | 72 |
31 Mar 18 | 6,204 | 160 | 1,987 | 62 |
31 Dec 17 | 5,676 | 119 | 1,740 | 58 |
30 Sep 17 | 5,271 | 98 | 1,470 | 26 |
30 Jun 17 | 5,176 | 60 | 1,416 | 0 |
31 Mar 17 | 5,016 | 39 | 1,318 | 0 |
31 Dec 16 | 4,814 | 24 | 1,236 | 0 |
30 Sep 16 | 4,581 | -156 | 1,204 | 0 |
30 Jun 16 | 4,122 | -295 | 1,204 | 0 |
31 Mar 16 | 4,031 | -358 | 1,223 | 0 |
31 Dec 15 | 3,834 | -384 | 1,153 | 0 |
30 Sep 15 | 4,006 | -194 | 1,078 | 0 |
30 Jun 15 | 4,092 | -77 | 1,009 | 0 |
31 Mar 15 | 4,223 | -8 | 1,039 | 0 |
31 Dec 14 | 4,333 | 87 | 1,077 | 0 |
30 Sep 14 | 4,260 | -27 | 1,224 | 0 |
30 Jun 14 | 4,199 | -56 | 1,226 | 0 |
31 Mar 14 | 4,022 | -77 | 1,178 | 0 |
31 Dec 13 | 3,871 | -167 | 1,130 | 0 |
양질의 수익: 000597 has a large one-off gain of CN¥206.2M impacting its last 12 months of financial results to 30th September, 2024.
이익 마진 증가: 000597's current net profit margins (4.3%) are lower than last year (5.1%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 000597's earnings have grown significantly by 35.5% per year over the past 5 years.
성장 가속화: 000597's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
수익 대 산업: 000597 had negative earnings growth (-21.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
자기자본 수익률
높은 ROE: 000597's Return on Equity (6.8%) is considered low.